PARP 抑制剂在卵巢癌中的应用：开拓与变革之旅。
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
机构信息
Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.
出版信息
Clin Cancer Res. 2018 Sep 1;24(17):4062-4065. doi: 10.1158/1078-0432.CCR-18-1314. Epub 2018 Jun 5.
Abstract
PARP inhibitors have transformed treatment for ovarian cancer, a cancer notable for homologous recombination (HR) deficiencies and aberrant DNA repair, especially in the high-grade serous subtype. PARP inhibitors are now approved for recurrent ovarian cancer as maintenance following response to platinum chemotherapy and -mutated (m) cancer treatment. .
摘要
聚腺苷二磷酸核糖聚合酶抑制剂改变了卵巢癌的治疗方式，这种癌症以同源重组（HR）缺陷和异常的 DNA 修复为特征，尤其是在高级别浆液性亚型中。PARP 抑制剂现获准用于铂类化疗反应后的维持治疗以及治疗-突变（m）癌症。
Zotero 插件